Welcome to our dedicated page for Stepan SEC filings (Ticker: SCL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Stepan Company filings document the regulatory record for a specialty and intermediate chemicals manufacturer whose common stock trades on the New York Stock Exchange under symbol SCL. Its 8-K filings report operating results, dividend declarations, material-event disclosures, capital-structure information and exit or disposal activities tied to manufacturing and efficiency initiatives.
Stepan proxy and annual-meeting filings cover director elections, advisory compensation votes, auditor ratification, executive compensation governance and benefit-plan matters. The filing record also includes disclosure on restructuring charges, asset write-downs, decommissioning costs and other governance or financial matters reported through current reports and proxy materials.
Stepan Company executive Robert Haire reported equity award activity involving Stepan Co. (SCL) common stock. On 12/31/2025, restricted stock units (RSUs) were settled in shares of common stock, resulting in the acquisition of 1,891 shares at a price of $47.205 per share. After this transaction, Haire beneficially owned 2,482 shares of common stock directly and 90.269 shares indirectly through an ESOP II Trust.
In connection with the RSU vesting, 574 RSUs were withheld to satisfy tax liabilities, leaving 1,318 RSUs beneficially owned following the reported transactions. Each RSU represents a contingent right to receive one share of Stepan Company common stock, and these RSUs vest ratably over two years beginning on the date shown.
Stepan Co director reports an insider stock transaction. A director of Stepan Co (ticker SCL) filed a Form 4 for a transaction dated 12/23/2025. The filing shows a gift transaction (code G) of 95.858 shares of Stepan common stock at a stated price of $0, reflecting a transfer without consideration. After this transaction, the director directly beneficially owns 126,219.262 shares of Stepan common stock.
The report also lists extensive indirect holdings in Stepan common stock through various vehicles, including an ESOP II trust, multiple family limited liability companies and family trusts, a spouse, a father, and an estate, with certain interests expressly disclaimed except to the extent of any pecuniary interest.
Stepan Company executive Richard F. Stepan, V.P. and General Manager of Polymers, reported an insider transaction involving the company’s common stock. On 12/23/2025, he reported a transaction coded "G," indicating a gift of shares at a price of $0 per share. After this transaction, he directly beneficially owned 241,116.15 shares of Stepan common stock.
In addition to his direct holdings, the filing lists indirect ownership through family members and trusts, including shares held by a daughter, a son, a spouse, a trust, and an ESOP II trust. This Form 4 reflects a change in how some shares are held and reported, rather than a market sale or purchase for cash.
Stepan Company has approved a new Key Executive Severance Benefit Plan effective November 26, 2025. The plan covers selected executives, including currently serving named executive officers, and is intended to provide severance compensation and benefits following certain involuntary terminations described as Qualifying Terminations.
Qualifying Terminations include an involuntary termination without cause and certain terminations that occur on or within 24 months after a change in control, including constructive terminations. Tier 1 executives are eligible for severance periods of 18 months for an involuntary termination without cause and 36 months for a change in control termination, while Tier 2 executives receive 12 months and 24 months, respectively. Severance is conditioned on the executive signing a release and complying with restrictive covenants, and equity awards continue to be governed by existing equity incentive plans and award agreements.
Stepan Company (SCL) — Officer equity grants reported. On 11/07/2025, the VP & CHRO reported awards of 1,159 Restricted Stock Units, 1,638 Stock Appreciation Rights with an exercise price of $43.15, and 579 performance shares.
The RSUs and SARs vest ratably over three years beginning 11/07/2026; the RSUs expire 11/07/2028 and the SARs expire 11/07/2035. The performance shares vest upon certification of performance goals for the period ending December 31, 2027.
Stepan Company (SCL) filed its quarterly report, showing mixed Q3 results. Net sales rose to $590,284,000, but net income declined to $10,839,000, with diluted EPS of $0.47. Operating income was $21,794,000 as higher interest expense weighed on results.
For the nine months, net sales reached $1,778,228,000 while net income was $41,891,000 with diluted EPS of $1.83. Cash and cash equivalents were $118,537,000, and total debt was $655,472,000. Operating cash flow was $87,891,000 and capital expenditures were $87,896,000.
By segment in Q3, Surfactants delivered $15,718,000 operating income, Polymers $14,104,000 and Specialty Products $9,634,000, offset by unallocated corporate expenses. Accumulated other comprehensive loss improved to $(138,608,000). The company recorded environmental and legal accruals of $19,406,000 and paid a $1,126,000 USEPA civil penalty, recovering $500,000. Assets held for sale include SPQI’s Philippines manufacturing assets with $8,476,000 of assets and $4,571,000 of liabilities, with closing planned in the fourth quarter of 2025.
Stepan Company announced it issued a press release with its financial results for the quarter ended September 30, 2025, and disclosed a separate dividend action.
The Board of Directors declared a quarterly cash dividend of $0.395 per share, payable on December 15, 2025, to shareholders of record as of November 28, 2025. The earnings press release is furnished as Exhibit 99.1, and the dividend press release is furnished as Exhibit 99.2.
Stepan Company announced it issued a press release with its financial results for the quarter ended September 30, 2025, and disclosed a separate dividend action.
The Board of Directors declared a quarterly cash dividend of $0.395 per share, payable on December 15, 2025, to shareholders of record as of November 28, 2025. The earnings press release is furnished as Exhibit 99.1, and the dividend press release is furnished as Exhibit 99.2.
Stepan Company (SCL) announced the resignation of Samuel S. Hinrichsen, Global Vice President, Finance and Investor Relations, effective October 31, 2025.
Hinrichsen previously served as Vice President and Interim Chief Financial Officer from October 30, 2024 to July 15, 2025. The company stated his resignation was not due to any disagreement with Stepan regarding operations, policies, or practices.
Stepan Co. (SCL) Form 3 filed for Andrea J. Barry, who is identified as Vice President & CHRO and an officer/director. The report covers the event date 09/30/2025 and states that no securities are beneficially owned by the reporting person. The filing is an initial statement and was signed by an attorney-in-fact on 10/07/2025. This is a routine Section 16 disclosure showing no direct or indirect holdings to report.
Stepan Company (SCL) insider filing shows officer Shawn G. Lisle received equity awards on 08/26/2025. The grant includes 3,462 Restricted Stock Units (RSUs) vesting ratably over three years, 1,731 Performance Shares that vest only if specified performance goals for the period ending 12/31/2027 are met, and a Stock Appreciation Right (SAR) covering 4,861 shares with an exercise price of $50.55 that vests over three years and expires 08/26/2035. Each RSU and performance share converts to one common share if earned. The filing is a standard Section 16 disclosure of officer compensation-related issuances and does not report any cash purchases or sales.